

# Challenges and Access to Viral Load Testing in Africa: Example of Cote d'Ivoire

Christiane Adje-Toure, PhD Lab Branch Chief CDC-COTE D'IVOIRE


www.iasociety.org



# Outline

- **1. Introduction**
- 2. Barriers to Scaling up Viral Load and Uptake
- **3. Demand Creation and Monitoring and Evaluation**
- 4. Conclusion






# Introduction




# **Progress in Viral Load Testing**



# U.S. Ambassador Birx's commitment to scale-up viral load testing




# **Progress in Cote d'Ivoire**



### **Guidelines Matter – Implementation is Challenging**

The error of a top-down approach



"I have shared my vision, so now we have a shared vision"

Cartoon by Mark de Koning






# Viral Load testing Scale-up S Cote d'Ivoire 2012 National Strategies

- National scale-up plan (identifies role of each stakeholder)
  - PEPFAR and ESTHER (lab, equipment and reagent)
  - Global fund laboratory reagents
  - ESTHER training of physicians
  - PEPFAR training of laboratory technicians
- All regional labs (18) to be equipped with a platform (national access)
- Preferred equipment leasing with reagent rental
- Laboratory training plan mapping the needs per region
- National external quality control program
- National VL database with a quarterly reporting to the central lab (LIS)





# Forecasted HIV Viral Load Testing Demand, 2015-2020




25,000,000

Source: WHO/CHAI



# Cote d'Ivoire Forecast and Results





## Barriers to scaling up viral load and uptake



## Key Barriers to Scaling up of Viral Load at National Level

- 1. Viral Load Networks -Sample Referral Systems
- Demand Creation and Uptake of Results – Role of Clinicians & Patients
- 3. Financing and Supply Chain Management
- 4. Monitoring and Evaluation
- 5. Human Resources

### Specific to Cote d'Ivoire (PEPFAR)

- Laboratory Infrastructure (electricity, equipment, space)
- 2. Sample transportation
- 3. Human Resources and demand creation
- 4. Viral load literacy (Laboratory, clinical and community)
- 5. Financing, Supply chain and Data collections

# **Barriers at Site Level**

- 1. Lack of review and analysis of laboratory data (VL test results) for program improvement in most site
- 2. Limited information captured in laboratory requisition forms
- 3. Weak implementation of SOPs at clinics and laboratories
- 4. Limited optimization of workflows and absence of focal points
- 5. Poor understanding of VL test reporting forms by clinicians in some site :
  - target not detected
  - below level of detection and suppression
    - <20 copies/ml
    - <1000 copies/ml



Morbidity and Mortality Weekly Report

November 27, 2015

#### Scale-up of HIV Viral Load Monitoring — Seven Sub-Saharan African Countries

Shirley Lecher, MD<sup>1</sup>; Dennis Ellenberger, PhD<sup>1</sup>; Andrea A. Kim, PhD<sup>1</sup>; Peter N. Fonjungo, PhD<sup>1</sup>; Simon Agolory, MD<sup>2</sup>; Marie Yolande Borget MS<sup>3</sup>; Laura Broyles, MD<sup>1</sup>; Sergio Carmona, MBBCh<sup>4</sup>; Geoffrey Chipungu, MBBS<sup>5</sup>; Kevin M. De Cock, MD<sup>6</sup>; Varough Deyde, PhD<sup>7</sup>; Marie Downer, MD<sup>6</sup>; Sundeep Gupta, MD<sup>5</sup>; Jonathan E. Kaplan, MD<sup>1</sup>; Charles Kiyaga, MPhil<sup>8</sup>; Nancy Knight, MD<sup>7</sup>; William MacLeod, Sc.D<sup>4</sup>; Boniface Makumbi<sup>9</sup>; Hellen Muttai, MBChB<sup>6</sup>; Christina Mwangi, MMed<sup>10</sup>; Jane W. Mwangi, MMed<sup>6</sup>; Michael Mwasekaga<sup>11</sup>; Lucy W. Ng'Ang'A, MBChB<sup>6</sup>; Yogan Pillay, PhD<sup>12</sup>; Abdoulaye Sarr, DSc<sup>5</sup>; Souleymane Sawadogo<sup>2</sup>; Daniel Singer, MD<sup>5</sup>; Wendy Stevens, MBBCh<sup>4</sup>; Christiane Adje Toure, PhD<sup>3</sup>; John Nkengasong, PhD<sup>1</sup>

# A Combination and Improved Strategies to Overcome Barriers

INNOVATIVE APPROACH FOR SAMPLE TRANSPORTATION

#### ELECTRONIC DASHBOARD SCORECARD

LAB HUBS AROUND REGIONAL LABS USE OF DBS & POC DISTANCE LEARNING COMMUNITY LAB-CLINICAL INTERFACE

**REDUCE TAT** 

FAST TRACT RESULTS FOR


PATIENTS FAILING ART

**DEMAND CREATION** 

www.iasociety.org



## Improving Efficiencies Across the Viral Load Testing Spectrum





#### DRIED BLOOD SPOT SAMPLES CAN BE USED FOR HIV-1 VIRAL LOAD TESTING WITH MOST CURRENTLY AVAILABLE VIRAL LOAD TECHNOLOGIES: A POOLED DATA META-ANALYSIS

LARA VOJNOV<sup>1\*</sup>, SERGIO CARMONA<sup>2</sup>, CLEMENT ZEH<sup>3</sup>, JESSICA MARKBY<sup>4</sup>, DEBRAH BOERAS<sup>3</sup>, MARTA R. PRESCOTT<sup>1</sup>, JESSICA A. JOSEPH<sup>1</sup>, ANTHONY L.H. MAYNE<sup>5</sup>, SOULEYMANE SAWADOGO<sup>3</sup>, MARIA MERCEDES PEREZ GONZALEZ<sup>6</sup>, WENDY S. STEVENS<sup>2</sup>, MEG DOHERTY<sup>6</sup>, TREVOR F. PETER<sup>1</sup>, CHUNFU YANG<sup>3</sup>, AND THE DBS FOR VL DIAGNOSTICS INVESTIGATION CONSORTIUM<sup>#</sup>

#### Field evaluation of Dried Blood Spots for HIV-1 viral load monitoring in adults and children receiving antiretroviral treatment in Kenya, 2013: Implications for scale-up in resource limited settings

Mary E. Schmitz, MPH<sup>1</sup>; Simon Agolory, MD <sup>2</sup>; Muthoni Junghae, PhD<sup>1</sup>; Laura N. Broyles, MD<sup>2</sup>; Muthusi Kimeu, MSc<sup>3</sup>; Joseph Ombayo, BSc<sup>4</sup>; Mamo Umuro, MSc<sup>4</sup>; Irene Mukui, MD<sup>5</sup>; Kennedy Alwenya, MA<sup>3</sup>; Moses Baraza, BSc<sup>3</sup>; Kenneth Ndiege, BSc<sup>3</sup>; Samuel Mwalili, PhD<sup>1</sup>; Emilia Rivadeneira, MD<sup>2</sup>; Lucy Ng'ang'a, MD<sup>1</sup>; Chunfu Yang, PhD<sup>2</sup>; Clement Zeh, PhD, MPH <sup>1</sup>; for VL-DBS Study Group.


Submitted to JAIDS for consideration of publication





## Demand Creation and Monitoring and Evaluation

## Creating the Demand for Viral Load



#### Challenge

- Lack of effective dissemination and translation of the guidelines into accessible job aids
- Awareness campaigns for patients and communities on the benefits of VL testing and its difference from CD4

#### Solutions

- Tools to help countries increase demand for viral load and to educate patients, community and clinicians on the use of viral load
- Identify focal points a each clinics and community with SOPs
- Improve Laboratory reagents
  supply chain
  Source: Randy Allen

## I A S <mark>X</mark>

Monitoring and switching of first-line antiretroviral therapy in adult treatment cohorts in sub-Saharan Africa: collaborative analysis



Andreas D Haas, Olivia Keiser, Eric Balestre, Steve Brown, Emmanuel Bissagnene, Cleophas Chimbetete, François Dabis, Mary-Ann Davies, Christopher J Hoffmann, Patrick Oyaro, Rosalind Parkes-Ratanshi, Steven J Reynolds, Izukanji Sikazwe, Kara Wools-Kaloustian, D Marcel Zannou, Gilles Wandeler, Matthias Egger, for IeDEA southern Africa, east Africa, and west Africa\*


- Even when routine viral load monitoring was in place, around 44% of patients with confirmed virological failure were not switched
- 22% of patients under routine viral load monitoring and 30% of those receiving targeted viral load monitoring switched regimen without any evidence of virological failure.




## CDC VL/EID Laboratory Weekly Monitoring and Reporting Tool

#### Week of September 20th

Week of September 20th														
aboratory	VL # Sample Received		VL #Sample VL l Tested		ending	#Sample	#Sample	EID #Sample Pending	<b>N</b> IIS	Number Kit used week		Stock Kits EID	Number ] Kit used week	
TOTAL	4	4919	7032	22	2065	379	460	483	1612.5	158		218	13.5	5
VL/EID Laboratory Name		Quality Indicator 1: TAT Délai d'exécution des analyses (Nbre de jours ouvrables depuis la réception de l'échantillon jusqu'à la mise à disponibilité des résultats d'analyse)			Quality Indicator 2: Sample rejection rate Nombre d'échantillons rejetés dans la semaine en précisant les motifs. (exple: 5 rejets dont 3 échantillons insuffisants / 2 coagulés)			Quality Indicator 3: Out of service due to reagent stockout Nombre d'interruptions de service dues à une rupture de stock de reactifs (preciser le nombre de jours)			Others Human ressources; Equipment Breakdown; Electricity Issues; Others consumables stock out			
VL:		) : 5 jours 45 jours			0		RAS		Echec : CAP/CTM : 2 plaques EID C6800 : 2 plaques					
CHU YOP		18.5			0			RAS			RAS			1
CHU Bouake		Non applicable: Pas de tests			37rejets dont 10 insuffisants, 9 codes discordants, 6 VIH2, 5 coagulés, 3 hémolysés, 2 éch. sans fiches, 2 fiches sans éch			RAS			Panne AmpliPrep depuis le 06/09/2017			
CHR Abengourou		CV=10			RAS			RAS		RAS				
CHR SAN-PEDRO		4 Jours			0			RAS		RAS		1		
CHR Yamoussoukro		EID 7 jours / CV 10jours			4 rejetés dont 2 echantillons insuffisants et 2 VIH 2			RAS			RAS			
CePRef Yopougon		47			0			RAS			RAS			
CHR Korhogo					23 réjets dont 5 échantillons insuffisants / 13 coagulés 1 VIH2 ; 4 prelevements non parvenus			RAS			Equipement en panne: AMPLIPREP			
HOPITAL Sou	HOPITAL Soubre		3		0			RAS			RAS			
		31 јот			2 rejets dont 1 pour discordance de numéro entre le tube et le bulletin/1 pour retard d'acheminement au labo			RAS		blocage du S tube dans le griper occasionnant la per d'une plaque		nt la perte	ł.	
CHR Man					0			RAS					1	
INSP Adjam		NON	I RENDU		coagul statut	dont 2 insuf és/ 1 hémolys VIH non rens	sé/ 3 de seigné	RAS		RAS				
IPCI			19		5 (2 ech	ecs QS invalide coagulés)	et 3 ech		RAS			www.jas	ociety.or	g




## Distribution of Patient with at Least one VL by District June 2017



Total Patients Patient with VL <1000copies</p>

www.iasociety.org





## **Conclusion**



# Conclusion

- Country National Plan
- Collaborative and multidisciplinary approach to scaling up viral load in National Plan
- Strong laboratory Network and Networking and best strategy for equipment and electricity management
- Focus on improving efficiencies
- Demand creation Clinicians, Community, Laboratory Personnel and Patients as drivers
- Scorecard or Tools to measure progress
- Strong Monitoring System